MedTrace Logo

AZD2014 and Weekly Paclitaxel in Squamous NSCLC

NCT02403895 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-07-03

Study results available
· View outcomes & findings →

Summary

Open--label, phase 2a, multi-centre, single-arm study to assess the efficacy and safety of AZD2014 and weekly paclitaxel in patients with squamous non-small cell lung cancer (NSCLC)

Conditions

  • Squamous Non Small Cell Lung Cancer

Interventions

DRUG

Open-label AZD2014

Dual TORC1/TORC2 inhibitor

DRUG

paclitaxel

Taxane

Sponsors & Collaborators

Principal Investigators

  • Chandra P Belani, MD · Hershey Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-15
Primary Completion
2016-12-29
Completion
2016-12-29

Countries

  • United States
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02403895 on ClinicalTrials.gov